General case Active pharmaceutical ingredients intended for storage in a refrigerator

92

2.1.7.1 General case

Study Storage condition Minimum time period covered by data at submission Long-term a 25 °C ± 2 °C60 RH ± 5 RH or 30 °C ± 2 °C65 RH ± 5 RH or 30 °C ± 2 °C75 RH ± 5 RH 12 months or 6 months as described in point 2.1.7 Intermediate b 30 °C ± 2 °C65 RH ± 5 RH 6 months Accelerated 40 °C ± 2 °C75 RH ± 5 RH 6 months a Whether long-term stability studies are performed at 25 °C ± 2 °C60 RH ± 5 RH or 30 °C ± 2 °C65 RH ± 5 RH or 30 °C ± 2 °C75 RH ± 5 RH is determined by the climatic condition under which the API is intended to be stored see Appendix 1. Testing at a more severe long-term condition can be an alternative to testing condition, i.e. 25 °C60 RH or 30 °C65 RH. b If 30 °C ± 2 °C65 RH ± 5 RH or 30 °C ± 2 °C75 RH ± 5 RH is the long-term condition there is no intermediate condition.

2.1.7.2 Active pharmaceutical ingredients intended for storage in a refrigerator

Study Storage condition Minimum time period covered by data at submission Long-term 5 °C ± 3 °C 12 months Accelerated a 25 °C ± 2 °C60 RH ± 5 RH or 30 °C ± 2 °C65 RH ± 5 RH or 30 °C ± 2 °C75 RH ± 5 RH 6 months a Whether accelerated stability studies are performed at 25 ± 2 °C60 RH ± 5 RH or 30 °C ± 2 °C65 RH ± 5 RH or 30 °C ± 2 °C75 RH ± 5 RH is based on a risk-based evaluation. Testing at a more severe long- term condition can be an alternative to storage testing at 25 °C60RH or 30 °C65RH. Data on refrigerated storage should be assessed according to the evaluation section of these guidelines, except where explicitly noted below. If signifi cant change occurs between three and six months’ testing at the accelerated storage condition, the proposed re-test period should be based on the data available at the long-term storage condition. If signifi cant change occurs within the fi rst three months’ testing at the accelerated storage condition a discussion should be provided to address the effect of short-term excursions outside the label storage condition, e.g. during shipping or handling. This discussion can be supported, if appropriate, by further testing on a single batch of the API for a period shorter than three months but with more frequent testing than usual. It is considered unnecessary to continue to test an API for the whole six months when a signifi cant change has occurred within the fi rst three months. 93

2.1.7.3 Active pharmaceutical ingredients intended for storage in a freezer